行情

IMMU

IMMU

Immunomedics
NASDAQ

实时行情|Nasdaq Last Sale

17.54
+0.24
+1.39%
盘后: 17.54 0 0.00% 17:06 11/15 EST
开盘
17.46
昨收
17.30
最高
17.82
最低
17.21
成交量
152.50万
成交额
--
52周最高
21.23
52周最低
11.55
市值
33.91亿
市盈率(TTM)
-11.6221
分时
5日
1月
3月
1年
5年

分析师评级

10位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

IMMU 新闻

  • Immunomedics to Present at Upcoming Healthcare Conferences
  • GlobeNewswire.3天前
  • Clovis (CLVS) Q3 Earnings & Sales Beat Estimates, Shares Up
  • Zacks.11/08 14:32
  • Immunomedics (IMMU) Reports Wider-Than-Expected Loss in Q3
  • Zacks.10/31 17:40
  • Edited Transcript of IMMU earnings conference call or presentation 30-Oct-19 9:00pm GMT
  • Thomson Reuters StreetEvents.10/31 14:13

更多

所属板块

生物技术和医学研究
+1.25%
制药与医学研究
+1.34%

热门股票

名称
价格
涨跌幅

IMMU 简况

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of six clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130). The Company also has a range of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various-stages of clinical and pre-clinical development.
展开

Webull提供Immunomedics, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。